175 related articles for article (PubMed ID: 18421299)
1. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells.
Zhou XD; Agazie YM
Cell Death Differ; 2008 Jun; 15(6):988-96. PubMed ID: 18421299
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.
Zhou X; Agazie YM
J Biol Chem; 2009 May; 284(18):12226-34. PubMed ID: 19261604
[TBL] [Abstract][Full Text] [Related]
3. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment.
Zhao H; Agazie YM
BMC Cancer; 2015 Mar; 15():109. PubMed ID: 25885600
[TBL] [Abstract][Full Text] [Related]
5. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
[TBL] [Abstract][Full Text] [Related]
6. SHP2 positively regulates TGFβ1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1.
Li S; Wang L; Zhao Q; Liu Y; He L; Xu Q; Sun X; Teng L; Cheng H; Ke Y
J Biol Chem; 2014 Dec; 289(49):34152-60. PubMed ID: 25331952
[TBL] [Abstract][Full Text] [Related]
7. Protein Tyrosine Phosphatase SHP2 Suppresses Host Innate Immunity against Influenza A Virus by Regulating EGFR-Mediated Signaling.
Wang Q; Pan W; Wang S; Pan C; Ning H; Huang S; Chiu SH; Chen JL
J Virol; 2021 Feb; 95(6):. PubMed ID: 33361428
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types.
Vazhappilly CG; Saleh E; Ramadan W; Menon V; Al-Azawi AM; Tarazi H; Abdu-Allah H; El-Shorbagi AN; El-Awady R
Invest New Drugs; 2019 Apr; 37(2):252-261. PubMed ID: 29947013
[TBL] [Abstract][Full Text] [Related]
9. EGF augments TGFβ-induced epithelial-mesenchymal transition by promoting SHP2 binding to GAB1.
Buonato JM; Lan IS; Lazzara MJ
J Cell Sci; 2015 Nov; 128(21):3898-909. PubMed ID: 26359300
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression.
Lo HW; Hsu SC; Xia W; Cao X; Shih JY; Wei Y; Abbruzzese JL; Hortobagyi GN; Hung MC
Cancer Res; 2007 Oct; 67(19):9066-76. PubMed ID: 17909010
[TBL] [Abstract][Full Text] [Related]
11. Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells.
Li Q; Mattingly RR
Neoplasia; 2008 Dec; 10(12):1444-58. PubMed ID: 19048123
[TBL] [Abstract][Full Text] [Related]
12. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
Hartman Z; Geldenhuys WJ; Agazie YM
J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
14. Taiwan cobra cardiotoxin III suppresses EGF/EGFR-mediated epithelial-to-mesenchymal transition and invasion of human breast cancer MDA-MB-231 cells.
Tsai PC; Fu YS; Chang LS; Lin SR
Toxicon; 2016 Mar; 111():108-20. PubMed ID: 26774845
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells.
Uttamsingh S; Bao X; Nguyen KT; Bhanot M; Gong J; Chan JL; Liu F; Chu TT; Wang LH
Oncogene; 2008 Apr; 27(18):2626-34. PubMed ID: 17982486
[TBL] [Abstract][Full Text] [Related]
16. Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation.
Wang J; Kuiatse I; Lee AV; Pan J; Giuliano A; Cui X
Mol Cancer Res; 2010 Feb; 8(2):266-77. PubMed ID: 20145041
[TBL] [Abstract][Full Text] [Related]
17. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells.
McPherson VA; Sharma N; Everingham S; Smith J; Zhu HH; Feng GS; Craig AW
J Immunol; 2009 Oct; 183(8):4940-7. PubMed ID: 19786542
[TBL] [Abstract][Full Text] [Related]
18. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis.
Zhou X; Coad J; Ducatman B; Agazie YM
Histopathology; 2008 Oct; 53(4):389-402. PubMed ID: 18643929
[TBL] [Abstract][Full Text] [Related]
19. Gamma tocotrienol targets tyrosine phosphatase SHP2 in mammospheres resulting in cell death through RAS/ERK pathway.
Gu W; Prasadam I; Yu M; Zhang F; Ling P; Xiao Y; Yu C
BMC Cancer; 2015 Aug; 15():609. PubMed ID: 26315028
[TBL] [Abstract][Full Text] [Related]
20. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
